Medical Patent News

RSS

Celera receives patent on KIF6 gene variant

Celera Corporation today announced that the United States Patent and Trademark Office has issued United States Patent 7,799,530 relating to methods of determining heart attack risk by detecting the KIF6 gene variant and reduction of such increased risk by statin therapy.

21 Sep 2010

ConfiDisc Syringe Injection System granted U.S. patent

Product innovators Chris and Sonia Hillios are pleased to announce that they have been granted a patent by the U.S. Patent and Trademark Office pertaining to their new syringe injection system, ConfiDisc(R).

21 Sep 2010

Talecris Biotherapeutics announces 2010 eALTA award recipients

Talecris Biotherapeutics GmbH announced yesterday the recipients of the 2010 European alpha1-antitrypsin Laurell's Training Awards (eALTA). The annual awards, sponsored by Talecris, provide two fellowships of 50,000 euros to young investigators whose research aims to enhance the understanding and treatment of alpha1-antitrypsin deficiency (AAT deficiency).

21 Sep 2010

ABL receives new patent for TherapyEdge and ViroScore technology

Advanced Biological Laboratories (ABL) S.A., a biomedical company engaged in the development and commercialization of personalized healthcare electronic medical record systems coupled with expert rules using decision support tools, is pleased to announce today that the Canadian Intellectual Property Office has issued a Notice of Allowance and the Patent Office of India has issued a new patent for our patent applications derived from our U.S. Patent Nos. 6,081,786 and 6,188,988 to Barry et al.

21 Sep 2010

Harbor BioSciences granted US patent for Triolex metabolic disease and anti-inflammation drug candidate

Harbor BioSciences, Inc. today announced that the company has received patent No. 7,776,845 from the United States Patent and Trademark Office which covers its lead metabolic disease and anti-inflammation drug candidate Triolex (HE3286). The patent claims cover compounds including Triolex and formulations that contain the drug or the other claimed compounds.

20 Sep 2010

Stereotaxis receives 100th patent for interventional medicine

Stereotaxis, Inc. today announced that the U.S. Patent and Trademark Office granted the Company its 100th patent, a major intellectual property milestone. The 100th patent, U.S. patent No. 7,772,950, covers the "Method and Apparatus for Dynamic Magnetic Field Control Using Multiple Magnets." The 100th patent reflects Stereotaxis' ongoing commitment to innovate and protect its leading position in robotic solutions for interventional medicine.

20 Sep 2010

HemCon to appeal permanent injunction on Marine Polymer patent

HemCon Medical Technologies, Inc., announced today that it will appeal a permanent injunction entered by a US District Court in New Hampshire based on a patent held by Marine Polymer Technologies, Inc.

18 Sep 2010

Shrink Nanotechnologies files patent for CellAlign tissue engineering technology

Shrink Nanotechnologies, Inc., an innovative nanotechnology company developing products and licensing opportunities in the alternative energy industry, medical diagnostics and sensors and biotechnology research and development tools businesses, announced today that certain patent applications related to its advanced tissue engineering technology platform, CellAlign, have been filed.

17 Sep 2010

China-Biotics files two new patent applications

China-Biotics, Inc., the leading developer, manufacturer and distributor of probiotics products in China, today announced that it has submitted two new patent applications to the State Bureau of Intellect Property.

17 Sep 2010

Amedica Corporation receives patents for total disc replacement technology

Amedica Corporation, a spinal and orthopaedic implant and instrument company focused on unique silicon nitride (SiN) ceramic technologies, announced today that it has been granted two United States patents for its total disc replacement (TDR) technology that features the use of silicon nitride in the construction of the complete implant.

16 Sep 2010

Quick-Med receives patent for MultiStat technology to treat Rosacea

Quick-Med Technologies, Inc., a life sciences company that is developing innovative technologies for the healthcare and consumer markets, announced that the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent No. 7,795,302 entitled "Use of Compositions for Treating Rosacea."

15 Sep 2010

ACT receives patent for RPE cells to treat retinal degeneration

Advanced Cell Technology, Inc., a leader in the field of regenerative medicine, announced today that it will be issued U.S. Patent Numbers 7,795,025 and 7,794,704 on Tuesday, September 14th, which continue to extend the company's patent portfolio covering its retinal pigment epithelial (RPE) cell programs.

15 Sep 2010

AMS receives favorable ruling in Davenport infringement lawsuit

American Medical Systems Holdings, Inc., a leading provider of world-class devices and therapies for male and female pelvic health, announced today that the company is pleased with yesterday's U.S. Court of Appeals for the Federal Circuit's ruling that reversed a summary judgment and finding for Biolitec, Inc.

15 Sep 2010

Metabolon receives patent for metabolic age analysis

Metabolon, Inc., leaders in global metabolomics, biomarker discovery and biochemical analysis, announced today the grant of US Patent 7,781,160 entitled "Biomarkers Related to Metabolic Age and Methods Using the Same". The USPTO awarded the patent to Metabolon on August 24, 2010. This is the 12th patent issued to Metabolon.

14 Sep 2010

COPAN awarded Japanese patent for invention of flocked swabs

COPAN announced this week that it has received the Japanese patent for the invention of flocked swabs, FLOQSwabs, for collection and transfer of biological samples. The Japanese flocked swabs patent (2007-523663) is the latest addition to a growing number of patents held by COPAN across the world for the use of flocked swabs for collection and transfer of biological samples, including the Australian patent (2004226798) granted earlier this year, a European patent that covers several countries (1608268), a Canadian patent (2515205), and New Zealand patent (541560).

14 Sep 2010

Momenta Pharmaceuticals receives patent for enoxaparin

Momenta Pharmaceuticals, Inc., a biotechnology company specializing in the characterization and engineering of complex drugs, announced today that on September 7, 2010 the U.S. Patent and Trademark Office issued U.S. Patent No. 7,790,466, entitled "Evaluating Mixtures of Low Molecular Weight Heparins By Chain Profiles or Chain Mapping".

14 Sep 2010

Genomas awarded method patent for PhyzioGenomics Technology

Genomas®, a biomedical company advancing DNA-Guided Medicine, has been awarded US Patent 7,747,392, entitled Physiogenomic Method for Predicting Clinical Outcomes of Treatment in Patients by the US Patent and Trademark Office.

13 Sep 2010

Amorcyte receives patent for chemotactic hematopoietic stem cell product

Amorcyte, Inc., a biopharmaceutical company developing cell therapy products to treat cardiovascular disease, today announced that it has been granted United States Patent number 7,794,705 titled "Compositions and Methods of Vascular Injury Repair." The patent contains both composition of matter and method claims surrounding therapeutic chemotactic hematopoietic stem cell products used in treating or repairing a vascular injury following an acute myocardial infarction (AMI), and delivery of the cell therapy.

13 Sep 2010

Preliminary injunction against CellzDirect, Invitrogen, and Life Technologies for Liverpool patent infringement

Celsis In Vitro, Inc. announced today that the United States District Court for the Northern District of Illinois in Chicago has entered a preliminary injunction against CellzDirect Inc., Invitrogen Corporation, and Life Technologies (the Defendants) due to their infringement of U.S. Patent No. 7,604,929 (the Liverpool™ patent).

13 Sep 2010

Medizone International files patent application for AsepticSure system

Medizone International, Inc. (OTC Bulletin Board, OTCQB: MZEI) announces it has filed an additional international patent application covering recent developments in its variant of AsepticSure designed for government use in bio-terrorism countermeasures.

10 Sep 2010